Focus Partners Wealth
ALLR icon

Focus Partners Wealth’s Allarity Therapeutics ALLR Stock Holding History

Focus Partners Wealth’s Portfolio ALLR Stock Details ALLR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$54.2K Buy
+51,628
New +$64.7K ﹤0.01% 2739

Other funds holding ALLR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
StoneX Group
StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Danske Bank
Danske Bank Copenhagen K, Denmark $50.1B AUM 35.17% 1-Year Est. Return

Focus Partners Wealth's ALLR Position: Q3 2026 in Review

Focus Partners Wealth opened a new position in Allarity Therapeutics (ALLR) in Q3 2026: 51,628 shares worth $54.2K. The stake represents ﹤0.01% of the portfolio and ranks #2739 among its holdings.

9 funds tracked by Wall St. Rank hold ALLR as of Q3 2026.

  • Focus Partners Wealth held 51,628 shares of Allarity Therapeutics worth $54.2K as of Q3 2026.
  • Allarity Therapeutics was a new Focus Partners Wealth position in Q3 2026.
  • Allarity Therapeutics made up ﹤0.01% of Focus Partners Wealth's portfolio in Q3 2026, its #2739 holding.
  • 9 funds tracked by Wall St. Rank held Allarity Therapeutics as of Q3 2026.

Based on Focus Partners Wealth's 13F filing for Q3 2026, filed 12 Nov 2026.